MEP21908A - Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same - Google Patents

Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same

Info

Publication number
MEP21908A
MEP21908A MEP-219/08A MEP21908A MEP21908A ME P21908 A MEP21908 A ME P21908A ME P21908 A MEP21908 A ME P21908A ME P21908 A MEP21908 A ME P21908A
Authority
ME
Montenegro
Prior art keywords
preparation
rimonabant
pharmaceutical compositions
compositions containing
containing same
Prior art date
Application number
MEP-219/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Alain Alcade
Gilles Anne-Archard
Corinne Gavory
Olivier Monnier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of MEP21908A publication Critical patent/MEP21908A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-219/08A 2001-11-08 2002-11-04 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same MEP21908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0114579A FR2831883B1 (fr) 2001-11-08 2001-11-08 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
PCT/FR2002/003765 WO2003040105A1 (fr) 2001-11-08 2002-11-04 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
MEP21908A true MEP21908A (en) 2010-06-10

Family

ID=8869285

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-219/08A MEP21908A (en) 2001-11-08 2002-11-04 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same

Country Status (33)

Country Link
US (2) US20050043356A1 (fr)
EP (1) EP1446384A1 (fr)
JP (2) JP4181994B2 (fr)
KR (2) KR20050043774A (fr)
CN (1) CN100412063C (fr)
AP (1) AP1830A (fr)
AR (1) AR037253A1 (fr)
AU (1) AU2002350869B2 (fr)
BR (1) BR0213931A (fr)
CA (1) CA2464145A1 (fr)
CO (1) CO5580827A2 (fr)
CR (1) CR7333A (fr)
EA (1) EA006771B1 (fr)
EC (1) ECSP045088A (fr)
FR (1) FR2831883B1 (fr)
GE (1) GEP20063894B (fr)
HR (1) HRP20040403A2 (fr)
HU (1) HUP0402043A3 (fr)
IL (2) IL161533A0 (fr)
IS (1) IS7226A (fr)
MA (1) MA27080A1 (fr)
ME (1) MEP21908A (fr)
MX (1) MXPA04004394A (fr)
NO (1) NO326648B1 (fr)
NZ (1) NZ532369A (fr)
OA (1) OA12721A (fr)
PL (1) PL369372A1 (fr)
RS (1) RS36904A (fr)
TN (1) TNSN04079A1 (fr)
TW (1) TW200302824A (fr)
UA (1) UA76776C2 (fr)
WO (1) WO2003040105A1 (fr)
ZA (1) ZA200402999B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
EP2308840A1 (fr) 2005-06-30 2011-04-13 Prosidion Limited Agonistes de GPCR
EP1816125A1 (fr) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Formes cristallines d'un antagoniste du récepteur cannabinoïde CB1 et son procédé de préparation
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2008038143A2 (fr) * 2006-06-22 2008-04-03 Medichem, S.A. Nouvelles formes solides du rimonabant et procédés de synthèse pour la préparation de celles-ci
WO2008044153A2 (fr) * 2006-08-29 2008-04-17 Medichem, S.A. Procédé de synthèse amélioré de rimonabant
EP2057144A4 (fr) * 2006-09-01 2010-06-02 Hetero Drugs Ltd Nouveaux polymorphes de rimonabant
US20100076197A1 (en) * 2006-09-11 2010-03-25 Hetero Drugs Limited Process for rimonabant
WO2008035023A1 (fr) * 2006-09-19 2008-03-27 Cipla Limited Formes polymorphes de rimonabant
WO2008056377A2 (fr) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Nouvelles formes du rimonabant
WO2008064615A2 (fr) * 2006-12-01 2008-06-05 Zentiva, A.S. Formes cristallines et amorphes du rimonabant et procédés permettant d'obtenir ces formes
EA017170B1 (ru) * 2006-12-18 2012-10-30 7ТиЭм ФАРМА А/С Модуляторы рецептора св1
ES2373181T3 (es) 2007-01-04 2012-02-01 Prosidion Ltd Agonistas de gpcr de piperidina.
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
EP2114936A1 (fr) 2007-01-04 2009-11-11 Prosidion Limited Agonistes de gpcr pipéridiniques
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
EP1944297A1 (fr) * 2007-01-09 2008-07-16 Miklós Vértessy Rimonabant solide et cristallin et procédés de préparation, ainsi que composition pharmaceutique correspondante
WO2008088900A2 (fr) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Formes polymorphes d'une base de rimonabant et procédés pour leur préparation
EP1953144A1 (fr) * 2007-01-30 2008-08-06 Sandoz AG Nouvelles formes polymorphes de N-pipéridino-5-(4-chlorophényl)-1-(2, 4-dichlorphényl)-4-méthyl-3-pyrazolecarboxamide
FR2919862A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919864A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919863A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919865A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919867A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009153804A1 (fr) * 2008-06-16 2009-12-23 Cadila Healthcare Limited Procédé de préparation de la forme 1 du rimonabant
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
CN114555557A (zh) 2019-10-16 2022-05-27 大塚制药株式会社 森塔纳法啶的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
WO2003015700A2 (fr) * 2001-08-15 2003-02-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogues du cannabinoide vasoconstricteurs
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
NO20041879D0 (no) 2004-05-07
IL161533A (en) 2010-05-31
ZA200402999B (en) 2005-04-20
JP4931874B2 (ja) 2012-05-16
IL161533A0 (en) 2004-09-27
NZ532369A (en) 2005-10-28
HUP0402043A2 (hu) 2005-01-28
AP2004003024A0 (en) 2004-06-30
EA006771B1 (ru) 2006-04-28
TNSN04079A1 (fr) 2006-06-01
TW200302824A (en) 2003-08-16
GEP20063894B (en) 2006-08-10
AP1830A (en) 2008-02-22
NO326648B1 (no) 2009-01-26
AR037253A1 (es) 2004-11-03
BR0213931A (pt) 2004-09-08
ECSP045088A (es) 2004-06-28
CN1582278A (zh) 2005-02-16
JP2009035547A (ja) 2009-02-19
FR2831883A1 (fr) 2003-05-09
FR2831883B1 (fr) 2004-07-23
KR20090089485A (ko) 2009-08-21
WO2003040105A1 (fr) 2003-05-15
OA12721A (fr) 2006-06-27
RS36904A (sr) 2006-10-27
AU2002350869B2 (en) 2007-07-26
KR20050043774A (ko) 2005-05-11
IS7226A (is) 2004-04-19
MA27080A1 (fr) 2004-12-20
CN100412063C (zh) 2008-08-20
HUP0402043A3 (en) 2009-07-28
JP2005508383A (ja) 2005-03-31
JP4181994B2 (ja) 2008-11-19
CO5580827A2 (es) 2005-11-30
MXPA04004394A (es) 2004-08-11
EA200400491A1 (ru) 2004-12-30
HRP20040403A2 (en) 2004-08-31
UA76776C2 (uk) 2006-09-15
NO20041879L (no) 2004-06-08
US20050043356A1 (en) 2005-02-24
US20100190827A1 (en) 2010-07-29
CA2464145A1 (fr) 2003-05-15
PL369372A1 (en) 2005-04-18
CR7333A (es) 2008-09-23
EP1446384A1 (fr) 2004-08-18

Similar Documents

Publication Publication Date Title
MEP21908A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
SE0101675D0 (sv) Novel composition
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
NO20044221L (no) Nye forbindelser
DK1537104T3 (da) Azabicycloalkylethere og deres anvendelse som alfa7-nAChR-agonister
EP1416933B8 (fr) Piperidines substituees utilisees comme modulateurs du recepteur de la melanocortine
BRPI0519726B8 (pt) composto de hemidrato de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina, composição compreendendo o referido composto e seus usos
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
SE0400284D0 (sv) Novel compounds
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
UA83648C2 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
HUP0400391A3 (en) New compounds, which are potent inhibitors of na+/ca2+ exchange and pharmaceutical compositions containing them
EP1831239B8 (fr) Procédé de synthèse de la gamma-lactone de l'acide 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bisméthylène -17 alpha- pregn-4- ène-3-one-21 carboxylique et intermédiaries-clés de ce procédé
NO20041573L (no) Aralkyl-tetrahydro-pyridiner, deres fremstilling og farmasoytiske preparater inneholdende de samme
MXPA05012300A (es) Derivados de benzotiofeno de sulfamato como inhibidores de sulfatasa esteroidea.
GEP20094744B (en) Novel naphthalenic derivatives, method for the preparation thereof, and pharmaceutical compositions containing same
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények